1,255 results on '"Rosti, G."'
Search Results
2. Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT)
3. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
4. Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
5. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors
6. Differences among young adults, adults and elderly chronic myeloid leukemia patients
7. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
8. A novel approach to nutrition in prevention and treatment of cancer: a provocative call
9. Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database
10. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party
11. The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia
12. S156: INTERNATIONAL, PROSPECTIVE STUDY COMPARING NILOTINIB VERSUS IMATINIB WITH EARLY SWITCH TO NILOTINIB TO OBTAIN SUSTAINED TREATMENT-FREE REMISSION IN PATIENTS WITH WITH CHRONIC MYELOID LEUKEMIA
13. P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS
14. P698: BOSUTINIB DOSE OPTIMIZATION IN THE SECOND-LINE TREATMENT OF ELDERLY CML PATIENTS: EXTENDED 3-YEAR FOLLOW-UP AND FINAL RESULTS OF THE BEST STUDY
15. P1706: CLINICAL UTILITY OF ONLINE MONITORING OF PATIENT-REPORTED SYMPTOMS IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN REAL-LIFE PRACTICE
16. S152: SETD2/H3K36ME3 DEFICIENCY SUSTAINS GENOMIC INSTABILITY AND ENHANCES CLONOGENIC POTENTIAL OF CHRONIC MYELOID LEUKEMIA (CML) PROGENITORS
17. P719: EFFICACY AND SAFETY OF BOSUTINIB IN LATER-LINE PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A SUB-ANALYSIS FROM THE PHASE 4 BYOND TRIAL
18. Autologous Transplantation in Breast Cancer in Europe and EBMT Data
19. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
20. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
21. First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
22. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
23. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib
24. The use of granulocytic colony stimulating factors in patients receiving chemotherapy for germ cell tumors
25. Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer
26. Differences among young adults, adults and elderly chronic myeloid leukemia patients
27. Joubert Syndrome: When to Suspect a Ciliopathy in a Patient with Liver Failure and Syndromic Phenotype
28. Leucemia mieloide cronica: valutazione dei costi e degli end-point clinici con il sistema LabNet
29. Phenotypic Spectrum revealed by two hits model mechanism in Neurodevelopmental Disorder patients with Syndromic and Recurrent CNVs
30. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib
31. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
32. Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry
33. IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis
34. Psychiatric and Psychosocial Concomitants of Abnormal Illness Behaviour in Patients with Cancer
35. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
36. High-dose chemotherapy with peripheral blood progenitor cell support for patients with non-small cell lung cancer: the experience of the European Group for Bone Marrow Transplantation (EBMT) Solid Tumours Working Party
37. Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer
38. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization
39. Dual tyrosine kinase inhibitors in chronic myeloid leukemia
40. High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)
41. First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party
42. Long-term follow-up of patients with poor prognosis germ cell tumor treated with early high-dose chemotherapy with hematopoietic progenitor cell support: a single-center experience
43. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients
44. Sexual functions after high-dose chemotherapy in survivors of germ cell tumors
45. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990–1999
46. High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II–IIIA breast cancer
47. A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia
48. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
49. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors
50. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.